Hwail Pharmaceutical Co.,Ltd. Stock: price and insider trades · South Korea
화일약품
No insider purchase over the last 90 days. The latest, by 오성첨단소재, was filed 02 Jul 2026.
Hwail Pharmaceutical Co.,Ltd.: what insiders have been doing
Hwail Pharmaceutical Co.,Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). The last twelve months, up to 5 November 2026, brought 15 filings signed by 11 insiders.
Purchases and sales both appear in the filings: 3 purchases (2 insiders, €2,733) and 11 sales (9 insiders, €1.2M). The amount is not disclosed for 12 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 major shareholder and 1 senior executive. One trade stands out by size: a sale of €1.2M from 오성첨단소재, disclosed on 10 April 2026, or 2.0% of market capitalisation.
Across the 2,656 companies tracked on its exchange, the median is 7 filings; at 15 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed 25 purchases and 16 sales.
The latest purchase dates back some time: it was published 129 days ago, on 2 July 2026. The median gap between a trade and its publication by DART (FSS) is 7 days. This delay matters because a trade only becomes useful information once it is public. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySale+3 other insiders
Since the insiders bought
- -47.3%Entry ₩10,390 · Close 04 Nov 2026 ₩5,480
- -6.0%Entry ₩11,750 · Close at T+365 ₩11,050
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 91,333 sharesKRXDART:20260702000539Canonical exit: 30 Sept 2026 (T+90)
- 128,283 sharesKRXDART:20260609000485Canonical exit: 7 Sept 2026 (T+90)
- 8,276,597 sharesShareKRXDART:20260416000409
- KRXDART:20260416000443
- 19,848,242 sharesShareKRXDART:20260416000438
- 8,171 sharesShareKRXDART:20260416000352
- 19,890 sharesShareKRXDART:20260416000344
- 5,400 sharesShareKRXDART:20260416000335
- 32,626 sharesShareKRXDART:20260416000348
- 14,610 sharesShareKRXDART:20260416000340
- 14,610 sharesShareKRXDART:20260416000325
- 212,183 shares1.97% mcap100.0% of flowKRXDART:20260410003592
- 5,000 shares@ ₩944.000.0046% mcap100.0% of flowShareKRXDART:20260323000609Canonical exit: 17 Jun 2026 (T+90)
- ●Executives0DART
- 1,700,000 sharesKRXDART:20260213002576
- 246,789 sharesShareKRXDART:20250808000514Canonical exit: 6 Nov 2025 (T+90)
- 878,363 sharesKRXDART:20250808000523Canonical exit: 6 Nov 2025 (T+90)
- 1,580,729 sharesKRXDART:20250808000512Canonical exit: 23 Oct 2025 (T+90)
- 631,574 sharesShareKRXDART:20250801001054Canonical exit: 30 Oct 2025 (T+90)
- 30,147,786 sharesKRXDART:20250702000439Canonical exit: 30 Sept 2025 (T+90)
25 of 68 declarations
About Hwail Pharmaceutical Co.,Ltd.
화일약품 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the manufacturing of pharmaceutical products and healthcare solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
